CN108137514A - 芳基取代的二环杂芳基化合物 - Google Patents

芳基取代的二环杂芳基化合物 Download PDF

Info

Publication number
CN108137514A
CN108137514A CN201680056980.4A CN201680056980A CN108137514A CN 108137514 A CN108137514 A CN 108137514A CN 201680056980 A CN201680056980 A CN 201680056980A CN 108137514 A CN108137514 A CN 108137514A
Authority
CN
China
Prior art keywords
alkyl
alkoxy
aryl
base
alkylidene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680056980.4A
Other languages
English (en)
Chinese (zh)
Inventor
X·张
X·郑
L·S·丘帕克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN108137514A publication Critical patent/CN108137514A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201680056980.4A 2015-07-30 2016-07-28 芳基取代的二环杂芳基化合物 Pending CN108137514A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562198706P 2015-07-30 2015-07-30
US62/198,706 2015-07-30
PCT/US2016/044388 WO2017019828A1 (en) 2015-07-30 2016-07-28 Aryl substituted bicyclic heteroaryl compounds

Publications (1)

Publication Number Publication Date
CN108137514A true CN108137514A (zh) 2018-06-08

Family

ID=56609996

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680056980.4A Pending CN108137514A (zh) 2015-07-30 2016-07-28 芳基取代的二环杂芳基化合物

Country Status (6)

Country Link
US (1) US10517870B2 (enExample)
EP (1) EP3328839A1 (enExample)
JP (1) JP2018525371A (enExample)
KR (1) KR20180030913A (enExample)
CN (1) CN108137514A (enExample)
WO (1) WO2017019828A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111440146A (zh) * 2020-05-15 2020-07-24 中国药科大学 一种具有par4拮抗活性的苯并三嗪类化合物及其应用
CN111440161A (zh) * 2020-05-15 2020-07-24 中国药科大学 一种具有par4拮抗活性的二环杂芳基类化合物及其应用
CN116041341A (zh) * 2022-11-24 2023-05-02 中国药科大学 一种喹唑啉类par4拮抗剂及其医药应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2805030T3 (es) 2016-07-14 2021-02-10 Bristol Myers Squibb Co Compuestos monocíclicos sustituidos con heteroarilo
EP3484894B1 (en) 2016-07-14 2020-08-19 Bristol-Myers Squibb Company Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as par4 inhibitors
EP3484878B1 (en) 2016-07-14 2020-08-19 Bristol-Myers Squibb Company Bicyclic heteroaryl substituted compounds
WO2018013770A1 (en) * 2016-07-14 2018-01-18 Bristol-Myers Squibb Company Bicyclic heteroaryl substituted compounds
WO2019113312A1 (en) * 2017-12-08 2019-06-13 Innocrin Pharmaceuticals, Inc. Anticancer compound process

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0559843B1 (en) * 1990-11-26 1994-09-14 E.I. Du Pont De Nemours And Company Substituted n-heterobicyclic herbicides
TW201210597A (en) * 2010-06-09 2012-03-16 Gilead Sciences Inc Inhibitors of hepatitis C virus
CN102753545A (zh) * 2009-12-15 2012-10-24 盐野义制药株式会社 具有血管内皮脂酶抑制活性的噁二唑衍生物
WO2014095775A1 (de) * 2012-12-20 2014-06-26 Bayer Pharma Aktiengesellschaft Bet-proteininhibitorische dihydrochinoxalinone

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1164459A (en) 1980-11-11 1984-03-27 Yung-Hsiung Yang Process for preparing (imidazo¬1,2-a|pyridine- 2-yl)-carbostyril or -3,4-dihydrocarbostyryl derivatives
TW279162B (enExample) 1991-09-26 1996-06-21 Mitsubishi Chem Corp
ATE246184T1 (de) 1996-11-06 2003-08-15 Darwin Discovery Ltd Chinoline und deren therapeutische verwendung
WO1999050254A1 (en) * 1998-03-31 1999-10-07 Warner-Lambert Company Quinoxalinones as serine protease inhibitors such as factor xa and thrombin
ZA200600424B (en) * 2003-08-01 2007-05-30 Genelabs Tech Inc Bicyclic imidazol derivatives against flaviviridae
US7501416B2 (en) * 2004-02-06 2009-03-10 Bristol-Myers Squibb Company Quinoxaline compounds and methods of using them
ES2652440T3 (es) * 2004-04-02 2018-02-02 OSI Pharmaceuticals, LLC Inhibidores de proteína cinasa heterobicíclicos sustituidos con anillo 6,6-bicíclico
MX2007008587A (es) * 2005-01-14 2007-09-07 Genelabs Tech Inc Derivados de indol para tratamiento de infecciones virales.
JP2009023986A (ja) * 2006-11-08 2009-02-05 Pharma Ip 抗癌剤としてのビアリール誘導体
EP2129379B1 (en) * 2007-02-20 2019-04-10 Novartis AG Imidazoquinolines as dual lipid kinase and mtor inhibitors
EP2150255A4 (en) * 2007-05-10 2011-10-05 Glaxosmithkline Llc CHINOXALINE DERIVATIVES AS P13 KINASE INHIBITORS
PE20090717A1 (es) * 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
AR066879A1 (es) * 2007-06-08 2009-09-16 Novartis Ag Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
WO2009021083A1 (en) * 2007-08-09 2009-02-12 Smithkline Beecham Corporation Quinoxaline derivatives as pi3 kinase inhibitors
IN2012DN05113A (enExample) * 2007-09-17 2015-10-23 Abbott Lab
KR101257158B1 (ko) * 2008-05-23 2013-04-23 노파르티스 아게 단백질 티로신 키나제 억제제로서의 퀴놀린 및 퀴녹살린의 유도체
WO2010052448A2 (en) 2008-11-05 2010-05-14 Ucb Pharma S.A. Fused pyrazine derivatives as kinase inhibitors
JP5762971B2 (ja) * 2008-12-03 2015-08-12 プレシディオ ファーマシューティカルズ インコーポレイテッド Ｈｃｖｎｓ５ａの阻害剤
EP2241557A1 (de) * 2009-04-02 2010-10-20 Æterna Zentaris GmbH Chinoxalin-Derivate und deren Anwendung zur Behandlung gutartiger und bösartiger Tumorerkrankungen
TWI428332B (zh) * 2009-06-09 2014-03-01 Hoffmann La Roche 雜環抗病毒化合物
US9340528B2 (en) * 2009-09-04 2016-05-17 Bayer Pharma Aktiengesellschaft Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
US20110274648A1 (en) * 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
PT2501698T (pt) 2009-11-18 2018-07-23 Nat Res Council Canada Monómeros fluorados, oligómeros e polímeros para utilização em dispositivos eletrónicos orgânicos
WO2012071414A2 (en) * 2010-11-22 2012-05-31 Board Of Regents Of The University Of Nebraska Quinoxaline compounds and uses thereof
PT2705029T (pt) * 2011-05-04 2019-02-01 Rhizen Pharmaceuticals S A Novos compostos como moduladores de proteína quinases
CN102532932B (zh) 2012-01-12 2014-01-08 复旦大学 一类含有吡嗪环的有机染料及其制备方法和应用
BR112014032346A2 (pt) * 2012-06-26 2017-06-27 Del Mar Pharmaceuticals métodos para tratamento de malignidades resistentes ao inibidor de tirosina-quinase em pacientes com polimorfismos genéticos ou desregulações de ahi1 mutações empregando dianidrogalactitol, diacetildianidrogalactitol, dibromodulcitol, ou análogos ou derivados destes
WO2015004533A2 (en) * 2013-06-21 2015-01-15 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0559843B1 (en) * 1990-11-26 1994-09-14 E.I. Du Pont De Nemours And Company Substituted n-heterobicyclic herbicides
CN102753545A (zh) * 2009-12-15 2012-10-24 盐野义制药株式会社 具有血管内皮脂酶抑制活性的噁二唑衍生物
TW201210597A (en) * 2010-06-09 2012-03-16 Gilead Sciences Inc Inhibitors of hepatitis C virus
WO2014095775A1 (de) * 2012-12-20 2014-06-26 Bayer Pharma Aktiengesellschaft Bet-proteininhibitorische dihydrochinoxalinone

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AMY K. SHEAFFER, ET AL: "A Small Molecule Inhibitor Selectively Induces Apoptosis in Cells Transformed by High Risk Human Papilloma Viruses", 《PLOS. ONE.》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111440146A (zh) * 2020-05-15 2020-07-24 中国药科大学 一种具有par4拮抗活性的苯并三嗪类化合物及其应用
CN111440161A (zh) * 2020-05-15 2020-07-24 中国药科大学 一种具有par4拮抗活性的二环杂芳基类化合物及其应用
CN111440146B (zh) * 2020-05-15 2022-10-21 中国药科大学 一种具有par4拮抗活性的苯并三嗪类化合物及其应用
CN111440161B (zh) * 2020-05-15 2023-04-14 中国药科大学 一种具有par4拮抗活性的二环杂芳基类化合物及其应用
CN116041341A (zh) * 2022-11-24 2023-05-02 中国药科大学 一种喹唑啉类par4拮抗剂及其医药应用
CN116041341B (zh) * 2022-11-24 2025-02-28 中国药科大学 一种喹唑啉类par4拮抗剂及其医药应用

Also Published As

Publication number Publication date
EP3328839A1 (en) 2018-06-06
JP2018525371A (ja) 2018-09-06
US10517870B2 (en) 2019-12-31
KR20180030913A (ko) 2018-03-26
US20180214445A1 (en) 2018-08-02
WO2017019828A1 (en) 2017-02-02

Similar Documents

Publication Publication Date Title
CN108137514A (zh) 芳基取代的二环杂芳基化合物
CN105636953B (zh) 1,4‑二取代的哒嗪衍生物及其用于治疗与smn缺乏相关的病症的用途
CN109689642B (zh) 经单环杂芳基取代的化合物
CN109689649B (zh) 经二环杂芳基取代的化合物
CN115594669B (zh) 一种并环类衍生物及其制备方法和医药用途
WO2023131277A1 (zh) Nlrp3炎症小体抑制剂及其应用
CN111909108B (zh) 联苯类化合物及其制备方法和医药用途
KR20180119582A (ko) 라이실 옥시다제의 인돌 및 아자인돌 할로알릴아민 유도체 억제제 및 이의 용도
CN107567450B (zh) 用作tnf抑制剂的杂环化合物
CN115894520A (zh) 一种大环k-ras g12c抑制剂及其制备方法和在药学上的应用
JP2024533551A (ja) ナフチルアミン構造を有する低分子化合物とその使用
CN107635992A (zh) 用作tnf抑制剂的三环杂环化合物
WO2020078402A1 (zh) 作为TGF-βR1抑制剂的化合物及其应用
WO2020200284A1 (zh) 三环类化合物制备方法及其在医药领域的应用
WO2020156017A1 (zh) 靶向泛素化降解brd4蛋白化合物及其制备方法和应用
WO2023165581A1 (zh) 一种吡啶类衍生物及其用途
CN116969918A (zh) 氟取代的吡啶酮类衍生物及其药物组合物、制备方法和用途
WO2023246837A1 (zh) 一类具有嘧啶并六元环结构的化合物、包含其的药物组合物及其应用
WO2023125376A1 (zh) 作为蛋白质聚集抑制剂的稠合双环杂芳基酰胺化合物
CN117903128A (zh) 一类ask1/pdk1双靶向抑制剂及其制备方法和应用
JP2023516790A (ja) 癌処置のためのｂｃｌ－２ファミリタンパク質調節化合物
WO2025252099A1 (zh) 一种吡咯并六元芳环化合物及其制备方法和应用
WO2025209499A1 (zh) Polθ抑制剂及其药物组合物和应用
WO2024061366A1 (zh) 具有磷酰化芳基结构的小分子化合物及其应用
HK40091491B (zh) 一类具有萘胺结构的小分子化合物及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned
AD01 Patent right deemed abandoned

Effective date of abandoning: 20211126